Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601) Abstract #2068

Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.
Aim(s): This prospective, multi-center, open label, phase II study (EudraCT:2016-002858-20) will evaluate the efficacy and safety of Durvalumab plus Tremelimumab within four different cohorts: Well-moderately differentiated lung NENs (1), grade 1-2 gastrointestinal NENs (2), grade 1-2 pancreatic NENs (3) and grade 3 GEP NENs (4).
Materials and methods: Pts included in the trial must have progressed to all standard therapies in each setting for lung and GEP grade 1-2 NENs up to 4 prior lines. For pts included in cohort 4, progression to platinum-based chemotherapy is mandatory. All pts will receive durvalumab 1500 mg every 28 days for 12 months, and tremelimumab 75 mg Q4W up to 4 doses/cycles. Retreatment is allowed after progression in the follow-up period. The primary endpoint for cohorts 1-3 is disease control rate at 9 months including the percentage of pts achieving complete or partial response, or stable disease according to RECIST v1.1; for cohort 4 the primary endpoint will be median overall survival. These endpoints will be assessed by investigators and confirmed by central radiological review. Secondary endpoints include median progression-free survival, safety and tolerability and a wide panel of biomarkers in blood and tumor samples.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Jorge Hernando-Cubero

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: PhD Paula Jimenez-Fonseca
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#2047 IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Salvatore Tafuto
#2199 Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET)
Introduction: Immunotherapy is being explored in many tumour types with encouraging results, but
its role in the management of NET is yet to be defined.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Clare Vesely